Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2009

Long-term risk of mortality and acute kidney injury during hospitalization after major surgery.

Annals of surgery

鈥�

2009

Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.

The American journal of pathology

鈥�

2009

Role of relaxin in maternal systemic and renal vascular adaptations during gestation.

Annals of the New York Academy of Sciences

鈥�

2009

Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

鈥�

2009

Urinary CD80 excretion increases in idiopathic minimal-change disease.

Journal of the American Society of Nephrology : JASN

鈥�

网红黑料